Patents by Inventor Mei Yee Vanessa DING

Mei Yee Vanessa DING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240018221
    Abstract: The invention relates generally to antigen-binding molecules that specifically bind to Myosin Heavy Chain 9 (MYH9) and uses thereof for the treatment of specific cancers, such as mast cell tumors. In one embodiment, the MYH9 is canine MYH9 and the antigen-binding molecule is an antibody. In another embodiment, the antigen-binding molecule is conjugated to a toxin, for the treatment of canine mast cell tumors.
    Type: Application
    Filed: October 26, 2021
    Publication date: January 18, 2024
    Applicant: Agency for Science, Technology and Research
    Inventors: Wey Jia FONG, Boon Hwa CHOO, Mei Yee Vanessa DING, Chui Ping CHIN
  • Patent number: 11820821
    Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: November 21, 2023
    Assignees: SINGAPORE HEALTH SERVICES PTE LTD, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Hau Wan Leung, Andre Boon Hwa Choo, Mei Yee Vanessa Ding, Shao Weng Daniel Tan, Narayanan Gopalakrishna Iyer
  • Publication number: 20220213189
    Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.
    Type: Application
    Filed: December 22, 2021
    Publication date: July 7, 2022
    Inventors: Hau Wan Leung, Andre Boon Hwa CHOO, Mei Yee Vanessa DING, Shao Weng Daniel TAN, Narayanan Gopalakrishna IYER
  • Patent number: 11306153
    Abstract: The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment conjugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, therapeutic use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: April 19, 2022
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Mei Yee Vanessa Ding, Boon Hwa Andre Choo, Wey Jia Fong
  • Patent number: 11236160
    Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: February 1, 2022
    Assignees: SINGAPORE HEALTH SERVICES PTE LTD, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Hau Wan Leung, Andre Boon Hwa Choo, Mei Yee Vanessa Ding, Shao Weng Daniel Tan, Narayanan Gopalakrishna Iyer
  • Publication number: 20200317812
    Abstract: The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment conjugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, therapeutic use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.
    Type: Application
    Filed: May 22, 2017
    Publication date: October 8, 2020
    Inventors: Mei Yee Vanessa DING, Boon Hwa Andre CHOO, Wey Jia FONG
  • Publication number: 20190233514
    Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.
    Type: Application
    Filed: October 10, 2017
    Publication date: August 1, 2019
    Inventors: Hau Wan LEUNG, Andre Boon Hwa CHOO, Mei Yee vanessa DING, Shao Weng Daniel Tan, Narayanan Gopalakrishna Iyer
  • Patent number: 10287547
    Abstract: This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hCENCs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed Peroxiredoxin-6 (Prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal endothelial cells from a mixture of cell.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: May 14, 2019
    Assignees: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, SINGAPORE HEALTH SERVICES PTE LTD
    Inventors: Mei Yee Vanessa Ding, Boon Hwa Andre Choo, Chui Ping Angela Chin, Jodhbir Singh Mehta, Gary Peh
  • Publication number: 20170037366
    Abstract: This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hCENCs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed Peroxiredoxin-6 (Prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal en dothelial cells from a mixture of cell.
    Type: Application
    Filed: April 11, 2014
    Publication date: February 9, 2017
    Inventors: Mei Yee Vanessa DING, Boon Hwa Andre CHOO, Chui Ping Angela CHIN, Jodhbir Singh MEHTA, Gary PEH